Success Metrics

Clinical Success Rate
100.0%

Based on 14 completed trials

Completion Rate
100%(14/14)
Active Trials
3(15%)
Results Posted
86%(12 trials)

Phase Distribution

Ph phase_1
6
30%
Ph phase_4
3
15%
Ph phase_2
4
20%
Ph phase_3
3
15%

Phase Distribution

6

Early Stage

4

Mid Stage

6

Late Stage

Phase Distribution16 total trials
Phase 1Safety & dosage
6(37.5%)
Phase 2Efficacy & side effects
4(25.0%)
Phase 3Large-scale testing
3(18.8%)
Phase 4Post-market surveillance
3(18.8%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

100.0%

14 of 14 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

3

trials recruiting

Total Trials

20

all time

Status Distribution
Active(3)
Completed(14)
Other(3)

Detailed Status

Completed14
unknown3
Recruiting3

Development Timeline

Analytics

Development Status

Total Trials
20
Active
3
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Phase 16 (37.5%)
Phase 24 (25.0%)
Phase 33 (18.8%)
Phase 43 (18.8%)

Trials by Status

completed1470%
unknown315%
recruiting315%

Recent Activity

Clinical Trials (20)

Showing 20 of 20 trials
NCT04375800Phase 2

Doravirine (DOR) in Human Immunodeficiency Virus (HIV)-Infected Children Aged 4 Weeks to <12 Years and <45 kg (MK-1439-066)

Recruiting
NCT04900974Phase 1

Single Dose Pharmacokinetics of Doravirine in HIV-infected Pregnant Women

Completed
NCT05630638Phase 4

Doravirine Dose Optimisation in Pregnancy

Recruiting
NCT05761509

"Observational Study on Tolerability and Observance of Post-exposure Prophylaxis With Doravirine in HIV Viral Risk"

Completed
NCT02275780Phase 3

Safety and Efficacy of Doravirine (MK-1439) in Participants With Human Immunodeficiency Virus 1 (HIV-1) (MK-1439-018)

Completed
NCT03894124Phase 1

Pharmacokinetics of Plasma Doravirine Once Daily Over 72 Hours Following Drug Intake Cessation in Healthy Volunteers

Completed
NCT04689737Phase 4

Removal of Doravirine by Hemodialysis in HIV-Infected Patients With End-stage Renal Disease (ESRD)

Completed
NCT04892654Phase 3

Efficacy of Doravirine + Dolutegravir Dual Therapy in the Context of Antiretroviral Therapy Switch

Recruiting
NCT04495348

Explorations Into the Mechanism for INSTI-associated Weight Gain: a Focus on Energy Balance

Completed
NCT03272347Phase 2

Islatravir (MK-8591) With Doravirine and Lamivudine in Participants Infected With Human Immunodeficiency Virus Type 1 (MK-8591-011)

Completed
NCT04097925Phase 2

Doravirine Concentrations and Antiviral Activity in Genital Fluids in HIV-1 Infected Individuals

Completed
NCT04079452Phase 3

Doravirine Concentrations and Antiviral Activity in Cerebrospinal Fluid in HIV-1 Infected Individuals

Completed
NCT05322083

HIV A6 Genome In ART Unsuccessful Patients On DOR

Unknown
NCT05202613

Non-Interventional Observational Retrospective Study to Evaluate Doravirine Based-regimens in HIV Infected Aged Patients (DORAge).

Unknown
NCT04334551Phase 4

HIV Switch Trial in Experienced Patients With Multiple Class Resistance Including NNRTI Resistance

Unknown
NCT01632345Phase 2

A Dose-Ranging Study to Compare Doravirine (MK-1439) Plus TRUVADA® Versus Efavirenz Plus TRUVADA® in Human Immunodeficiency Virus (HIV)-1 Infected Participants (MK-1439-007)

Completed
NCT02715700Phase 1

Effects of Doravirine (MK-1439) on Methadone Pharmacokinetics in Methadone-Maintained Participants (MK-1439-045)

Completed
NCT01466985Phase 1

A Study of Doravirine (MK-1439) in Human Immunodeficiency Virus Type 1 (HIV-1)-Infected Participants (MK-1439-005)

Completed
NCT02641067Phase 1

A Study Evaluating the Pharmacokinetics of Doravirine (MK-1439) in Participants With Severe Renal Impairment (MK-1439-051)

Completed
NCT02089659Phase 1

A Study to Investigate the Influence of Hepatic Insufficiency on the Pharmacokinetics of Doravirine (MK-1439) (MK-1439-019)

Completed

All 20 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
20